These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19228724)

  • 1. Pharmacologic unmasking of epigenetically silenced genes in breast cancer.
    Ostrow KL; Park HL; Hoque MO; Kim MS; Liu J; Argani P; Westra W; Van Criekinge W; Sidransky D
    Clin Cancer Res; 2009 Feb; 15(4):1184-91. PubMed ID: 19228724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity.
    Guerrero-Preston R; Hadar T; Ostrow KL; Soudry E; Echenique M; Ili-Gangas C; Pérez G; Perez J; Brebi-Mieville P; Deschamps J; Morales L; Bayona M; Sidransky D; Matta J
    Oncol Rep; 2014 Aug; 32(2):505-12. PubMed ID: 24927296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy.
    Horne HN; Lee PS; Murphy SK; Alonso MA; Olson JA; Marks JR
    Mol Cancer Res; 2009 Feb; 7(2):199-209. PubMed ID: 19208741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic silencing of MAL, a putative tumor suppressor gene, can contribute to human epithelium cell carcinoma.
    Cao W; Zhang ZY; Xu Q; Sun Q; Yan M; Zhang J; Zhang P; Han ZG; Chen WT
    Mol Cancer; 2010 Nov; 9():296. PubMed ID: 21092172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of guanine nucleotide-binding protein γ-7 as an epigenetically silenced gene in head and neck cancer by gene expression profiling.
    Demokan S; Chuang AY; Chang X; Khan T; Smith IM; Pattani KM; Dasgupta S; Begum S; Khan Z; Liegeois NJ; Westra WH; Sidransky D; Koch W; Califano JA
    Int J Oncol; 2013 Apr; 42(4):1427-36. PubMed ID: 23403885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer.
    Buffart TE; Overmeer RM; Steenbergen RD; Tijssen M; van Grieken NC; Snijders PJ; Grabsch HI; van de Velde CJ; Carvalho B; Meijer GA
    Br J Cancer; 2008 Dec; 99(11):1802-7. PubMed ID: 19002170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma.
    Yamashita K; Kim MS; Park HL; Tokumaru Y; Osada M; Inoue H; Mori M; Sidransky D
    Mol Cancer Res; 2008 Jan; 6(1):31-41. PubMed ID: 18234960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
    Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
    Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypermethylated MAL gene - a silent marker of early colon tumorigenesis.
    Lind GE; Ahlquist T; Kolberg M; Berg M; Eknaes M; Alonso MA; Kallioniemi A; Meling GI; Skotheim RI; Rognum TO; Thiis-Evensen E; Lothe RA
    J Transl Med; 2008 Mar; 6():13. PubMed ID: 18346269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer.
    Wolf I; Bose S; Desmond JC; Lin BT; Williamson EA; Karlan BY; Koeffler HP
    Breast Cancer Res Treat; 2007 Oct; 105(2):139-55. PubMed ID: 17295047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer.
    Fujikane T; Nishikawa N; Toyota M; Suzuki H; Nojima M; Maruyama R; Ashida M; Ohe-Toyota M; Kai M; Nishidate T; Sasaki Y; Ohmura T; Hirata K; Tokino T
    Breast Cancer Res Treat; 2010 Aug; 122(3):699-710. PubMed ID: 19859801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E4BP4 is a repressor of epigenetically regulated SOSTDC1 expression in breast cancer cells.
    Rawat A; Gopisetty G; Thangarajan R
    Cell Oncol (Dordr); 2014 Dec; 37(6):409-19. PubMed ID: 25338303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
    Shames DS; Girard L; Gao B; Sato M; Lewis CM; Shivapurkar N; Jiang A; Perou CM; Kim YH; Pollack JR; Fong KM; Lam CL; Wong M; Shyr Y; Nanda R; Olopade OI; Gerald W; Euhus DM; Shay JW; Gazdar AF; Minna JD
    PLoS Med; 2006 Dec; 3(12):e486. PubMed ID: 17194187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer.
    Kang S; Dong SM; Park NH
    Gynecol Oncol; 2010 Jul; 118(1):58-63. PubMed ID: 20421128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic genome-wide analysis identifies BEX1 as a candidate tumour suppressor gene in paediatric intracranial ependymoma.
    Karakoula K; Jacques TS; Phipps KP; Harkness W; Thompson D; Harding BN; Darling JL; Warr TJ
    Cancer Lett; 2014 Apr; 346(1):34-44. PubMed ID: 24333734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.
    Roll JD; Rivenbark AG; Jones WD; Coleman WB
    Mol Cancer; 2008 Jan; 7():15. PubMed ID: 18221536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
    Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
    Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer.
    Fu DY; Wang ZM; Li-Chen ; Wang BL; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2010 Feb; 119(3):601-12. PubMed ID: 19301122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma.
    Jee CD; Kim MA; Jung EJ; Kim J; Kim WH
    Eur J Cancer; 2009 May; 45(7):1282-1293. PubMed ID: 19195878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.